Abstract T6: Adipocyte Bardet-Biedl Syndrome 1 Gene Is Critical For Blood Pressure Regulation

Hypertension ◽  
2021 ◽  
Vol 78 (Suppl_1) ◽  
Author(s):  
Yuying Zhao ◽  
Deng-Fu Guo ◽  
Kamal Rahmouni

Bardet-Biedl syndrome (BBS) proteins have emerged as critical regulators of various physiological functions including blood pressure. The presence of hypertension in BBS patients is consistent with the finding that BBS knockout mice exhibit increased renal sympathetic nerve activity and arterial pressure. However, the role and contribution of Bbs genes in various tissues such as adipose tissue to blood pressure regulation remains unclear. To address this, we generated a novel conditional knockout mouse that lacks the Bbs1 gene in adipocytes by breeding mice bearing floxed alleles of the Bbs1 gene (Bbs1 flox/flox ) with mice expressing Cre specifically in adipocytes (Adiponectin Cre mice). Cre-mediated recombination was verified by loss of Bbs1 expression in fat pads, but not in other tissues such as the kidneys, liver and skeletal muscle. Next, we assessed whether adipocyte Bbs1 gene deletion affects body weight and glucose homeostasis. Interestingly, no body weight phenotype was observed in both male and female Adipo Cre /Bbs1 flox/flox mice compared to their control littermates (males: 40.5±2.9 g vs 37.4±5.1 g; female: 27.7±4.0 g vs 27.5±3.6 g; 16 weeks old). However, insulin tolerance test uncovered impaired insulin-induced glucose clearance in both male and female Adipo Cre /Bbs1 flox/flox mice. Subsequently, we measured blood pressure and found that Adipo Cre /Bbs1 flox/flox mice have a remarkable increase in systolic blood pressure (130.4±11.2 mmHg) compared to the control littermates (119.1±4.5 mmHg, p <0.05). Finally, measurement of the expression of the renin-angiotensin system components revealed significantly elevated angiotensinogen mRNA (2.43±1.31 AU vs 1±0.72 AU, p <0.01) and angiotensin-converting enzyme mRNA (2.96±2.51 AU vs 1±0.95 AU, p <0.05) in peri-renal adipose tissue, but not in other fat pads such as brown and inguinal adipose tissues. Interestingly, gene expression of angiotensin receptor 1a was not significantly altered by Bbs1 gene deletion. Taken together, our findings demonstrate that Bbs1 gene in adipose tissue play an important role in the control of insulin sensitivity and blood pressure.

Hypertension ◽  
2017 ◽  
Vol 70 (suppl_1) ◽  
Author(s):  
David J Ferland ◽  
Bridget Seitz ◽  
Emma S Darios ◽  
Janice M Thompson ◽  
Steve T Yeh ◽  
...  

Chemerin is an inflammatory adipokine positively associated with hypertension and obesity with the majority of chemerin thought to derive from the liver and adipose tissue. The contributions of liver-derived chemerin to plasma chemerin levels and blood pressure regulation are unknown. We compared whole-body vs liver chemerin inhibition using antisense oligonucleotides (ASO) with liver-restricted activity (GalNAc) or liver and fat activity (Gen 2.5). We hypothesized that in normotensive male SD rats, circulating chemerin is predominately liver-derived and regulates blood pressure. A scrambled ASO control and phosphate-buffered saline (PBS) were used as controls and radiotelemetry was used to monitor blood pressure. Baseline mean arterial blood pressure (MAP) was recorded for one week, beginning 5 days after surgery to establish a baseline. ASOs were given weekly by subcutaneous injections for four weeks. Two days after the final injection, animals were sacrificed for tissue RT-PCR and plasma chemerin measurements using Western analysis. Gen 2.5 chemerin ASO treatments (compared to PBS control) reduced chemerin mRNA in liver, retroperitoneal fat, and mesenteric perivascular adipose tissue (mPVAT) by 99.5% ± 0.1%, 95.2% ± 0.3%, and 69% ± 2%, respectively, and plasma chemerin was reduced to undetectable levels. GalNAc chemerin ASO treatments (compared to PBS control) reduced chemerin mRNA in liver by 97.9% but had no effect on chemerin expression in retroperitoneal fat and mPVAT; plasma chemerin was reduced by 90% ± 5%. Gen 2.5 chemerin ASO treatment reduced MAP, which reached a nadir of 7 ± 2.1 mmHg 48 – 72 hours after each dose compared to the scrambled ASO controls. By contrast, MAP was unchanged in animals receiving the GalNAc chemerin ASO. Thus, although most circulating chemerin is liver-derived, plasma chemerin does not play a role in blood pressure regulation. This study suggests that while chemerin is still generally associated with increased blood pressure, circulating chemerin levels cannot directly predict this effect. In addition, local effects of chemerin from fat may explain this discrepancy and support chemerin’s association with both hypertension and obesity.


1996 ◽  
Vol 63 (3) ◽  
pp. 423S-425S ◽  
Author(s):  
D A McCarron ◽  
M E Reusser

2016 ◽  
Vol 7 (1) ◽  
Author(s):  
Wioletta Pijacka ◽  
Bethan Clifford ◽  
Dawid Walas ◽  
Chantal Tilburgs ◽  
Jaap A. Joles ◽  
...  

2001 ◽  
Vol 15 (14) ◽  
pp. 1-25 ◽  
Author(s):  
Florence Massiéra ◽  
May Bloch-Faure ◽  
Debbie Ceiler ◽  
Kazuo Murakami ◽  
Akiyoshi Fukamizu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document